GV, Tencent and Gilead Sciences will exit the vaccine and infectious disease drug developer in an initial public offering sized at about $110m.
Vaccitech, a UK-based vaccine developer that counts corporates Tencent, Alphabet, and Gilead Sciences as investors, will raise about $110m when it begins trading on the Nasdaq Global Market today. The company will issue 6.5 million American Depositary Shares (ADSs), each representing one ordinary share. It priced them at $17.00 each, at the midpoint of the…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.